BioNTech updates Phase 2/3 trial of BNT113 cancer immunotherapy
BioNTech provided an update on its Phase 2/3 clinical trial of BNT113, an mRNA cancer immunotherapy candidate for metastatic HPV16-positive head and neck cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.